Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Opsona Therapeutics (Ireland) | Researchclopedia

Back to institutions

Opsona Therapeutics (Ireland)

Dublincompany

34

Works

7,803

Citations

48

h-index

Top Research Topics

Immune Response and Inflammation NF-κB Signaling Pathways Helicobacter pylori-related gastroenterology studies

Top Researchers

Luke O'neill Environment Agency

709 works96,289 citationsh-index: 143

Recent Research

Abstract 251: Targeting cyclin K-CDK12 synergizes with ATR inhibition by limiting RPA chromatin loading in triple-negative breast cancer.

Eun‐Bee Choi,Sophia Podeszwa,et al.

20260 citations

Advanced Breast Cancer Therapies

Inflammatory mediators and NSAID effects

Pharmacogenetics and Drug Metabolism

Cancer-related Molecular Pathways

Pulmonary Hypertension Research and Treatments

Immune Cell Function and Interaction

Cardiac Ischemia and Reperfusion

Colorectal Cancer Treatments and Studies

Neuroinflammation and Neurodegeneration Mechanisms

Gerard Pasterkamp Utrecht University

870 works49,019 citationsh-index: 103

Dominique P.V. de Kleijn Utrecht University

424 works24,273 citationsh-index: 74

Mary M. Reilly National Hospital for Neurology and Neurosurgery

843 works23,023 citationsh-index: 81

Jean L. Grem University of Nebraska Medical Center

291 works18,682 citationsh-index: 57

Fatih Arslan Leiden University Medical Center

105 works9,887 citationsh-index: 31

Abstract PS1-08-06: Results of the phase 2 SUMIT-BC study, a randomized controlled trial of the cyclin-dependent kinase 7 inhibitor (CDK7i) samuraciclib with fulvestrant in advanced hormone receptor positive (HR+) breast cancer after a CDK4/6 inhibitor (CDK4/6i)

S. Pernas,C. Karaçin,et al.

20260 citations

326P Patient selection biomarkers for CDK7 inhibitor samuraciclib (SAM; CT7001) combined with selective estrogen receptor degrader (SERD) in hormone receptor-positive advanced breast cancer (HR+ ABC) post-CDK4/6 inhibitor (CDK4/6i)

M. Oliveira,B. Bermejo,et al.

20251 citations

Abstract 7004: CT7439 an oral first-in class selective CDK12 and 13 inhibitor and cyclin K degrader: Profiling activity and combination efficacy in an ovarian cancer model

Ashwani Bahl,Matthew T. Carr,et al.

20253 citations

365P Interim analysis (IA) of the giredestrant (G) + samuraciclib (SAMURA) arm in MORPHEUS breast cancer (BC): A phase I/II study of G treatment (tx) combinations in patients (pts) with oestrogen receptor-positive (ER+), HER2-negative, locally advanced/metastatic BC (LA/mBC)

Mafalda Oliveira,M. Gion Cortes,et al.

20243 citations

Imaging Carotid Plaque Inflammation Using Positron Emission Tomography: Emerging Role in Clinical Stroke Care, Research Applications, and Future Directions

John McCabe,Nicholas R. Evans,et al.

20233 citations